Implementing Novel Immunotherapy Agents in NMIBC Practice

The expert faculty discuss practical and logistical considerations for integrating novel immunotherapies into clinical management of high-risk non–muscle invasive bladder cancer (NMIBC). They note that while many urology and oncology practices already have clinical trial infrastructure, broader implementation will require dedicated teams, training, and workflow coordination. Key operational factors include managing infusion or subcutaneous administration schedules, coordinating with interventional radiology for port placement, and ensuring staff are educated on immune-related adverse event recognition and triage. The panelists emphasize that consistent communication between urologic and medical oncology teams is essential to synchronize systemic immunotherapy with intravesical BCG and cystoscopic surveillance. They also suggest using shared scheduling tools to help patients adhere to treatment timelines. Initially, many practices may centralize these services among experienced physicians before expanding access as confidence and familiarity grow. This cautious, structured rollout aims to optimize safety, efficiency, and patient experience.